Page last updated: 2024-12-10

20-carboxyleukotriene b4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

20-carboxyleukotriene B4: metabolite of leukotriene B4 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

20-hydroxy-20-oxoleukotriene B4 : A member of the class of leukotrienes that is leukotriene B4 in which the terminal methyl group has undergone formal oxidation to the corresponding carboxylic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280877
CHEMBL ID1592630
CHEBI ID27562
SCHEMBL ID4958126
MeSH IDM0099929

Synonyms (34)

Synonym
(5s,6z,8e,10e,12r,14z)-5,12-dihydroxyicosa-6,8,10,14-tetraenedioic acid
80434-82-8
20-hydroxy-20-oxoleukotriene b4
CHEBI:27562 ,
5(s),12(r)-dihydroxy-20-carboxy-6,8,10,14-eicosatetraenoic acid
6,8,10,14-eicosatetraenedioic acid, 5,12-dihydroxy-, (s-(r*,s*-(e,z,e,z)))-
LMFA03020016 ,
5s,12r-dihydroxy-6z,8e,10e,14z-eicosatetraene-1,20-dioic acid
20-carboxy-ltb4
20-carboxy-leukotriene b4
C05950
20-cooh-leukotriene b4
20-cooh-ltb4
20-carboxy-leukotriene b4, ~1 mg/ml in ethanol, >=90% (hplc)
NCGC00161275-01
20-carboxyleukotriene b4
BML1-E06
SCHEMBL4958126
CHEMBL1592630
(s-(r*,s*-(e,z,e,z)))-5,12-dihydroxy-6,8,10,14-eicosatetraenedioic acid
5(s),12(r)-dihydroxy-20-carboxy-6,8,10,14-eicosatetraenoate
5s,12r-dihydroxy-6z,8e,10e,14z-eicosatetraene-1,20-dioate
20-carboxy-leukotriene- b4
20-hydroxy-20-oxo-leukotriene b4
(s-(r*,s*-(e,z,e,z)))-5,12-dihydroxy-6,8,10,14-eicosatetraenedioate
20-carboxy-leukotrieneb4
Q27103196
SR-01000946892-1
sr-01000946892
DTXSID301313358
20-carboxy leukotriene b4
CS-0062374
PD021023
HY-113483
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
leukotrieneAny icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated.
alpha,omega-dicarboxylic acid
hydroxy carboxylic acidAny carboxylic acid with at least one hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (50)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Leukotrienes (LT) and Eoxins (EX)1329
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Eicosanoid metabolism via lipooxygenases (LOX)040
Leukotriene metabolic pathway219
Arachidonic acid (AA, ARA) oxylipin metabolism076
Eicosanoid metabolism via lipoxygenases (LOX)040
Arachidonic acid metabolism via LOX (Lipooxygenase) pathway033

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CruzipainTrypanosoma cruziPotency8.28520.002014.677939.8107AID1476; AID1478
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (66.67)18.7374
1990's5 (27.78)18.2507
2000's1 (5.56)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.09 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.04 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (5.56%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]